PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation

Features new ForeSite™ clinical trial methodology designed to reliably predict site successLONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, is launching its Connected Journey™ of data-driven services. This newly integrated network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology, processes, and expertise to deliver critical intelligence... Source: RealWire

Read More